Healwell AI's Margin Pivot Hangs in the Balance as Analysts Hold the Line

Healwell AI's Q2 shows flat revenue and lower EBITDA, but analysts keep buy ratings while trimming price targets; stock edges up 4.3%.

The market's verdict on Healwell AI's latest quarterly report has been characteristically split: analysts are trimming price targets while keeping their buy ratings intact, and investors are cautiously nudging the stock higher even as the company's core profitability metrics head in the wrong direction.

Shares in the healthcare AI specialist have clawed back 4.3 percent over the past seven trading sessions, with the equity changing hands at €0.4565 — just above its 50-day moving average. That tentative stabilization comes despite a second-quarter performance that saw revenue stall at C$33.0 million, essentially flat against the prior year's C$33.25 million, while adjusted EBITDA fell to C$1.1 million from C$2.3 million.

The company attributes the margin compression to the fourth-quarter 2025 divestment of its Mutuo subsidiary and a weaker mix within its Data Science & AI segment. Management has framed the current period as the "trough of integration" as it transitions toward an enterprise model built on recurring revenue.

Analysts Trim Targets, Not Conviction

The analyst response, delivered on August 11, tells a story of tempered enthusiasm rather than abandonment. TD Cowen reaffirmed its buy recommendation but lowered its price target to C$1.75, citing sector-wide multiple compression across SaaS names despite what it called Healwell's strong positioning in healthcare AI. Stifel Nicolaus trimmed its target from C$2.50 to C$2.25 while maintaining its buy rating, and Ventum Financial made the most aggressive cut, slashing its target from C$2.50 to C$1.75.

TD Securities held its C$1.75 target steady, while Maxim Group sat at the top of the range with C$2.00. Alliance Global Partners had already weighed in on August 7 with a buy rating and C$1.50 target, and Haywood's Gianluca Tucci highlighted the company's shift toward a higher-quality, recurring SaaS revenue base as a positive development.

A Split Screen: Bottom Line Improves, Top Line Stalls

The headline numbers present an unusually bifurcated picture. Net income from continuing operations swung to a profit of C$6.4 million against a C$4.1 million loss in the year-ago quarter — a swing driven in part by the value of the company's indirect stake in SpaceX, which was marked at roughly C$23 million as of June 30. Once lock-up restrictions lapse, Healwell plans to monetize that position to bolster liquidity.

For the first half, revenue climbed 60 percent to C$66.2 million from C$41.2 million, propelled by the Orion Health acquisition completed on April 1, 2025. Operating cash flow turned positive at C$4.5 million, a C$14.3 million improvement year over year. Gross margin slipped modestly to 54 percent from 56 percent on a quarterly basis.

The 10 Percent Question

The central test remains the company's pledge to reach an adjusted EBITDA margin of roughly 10 percent by year-end 2026. Management has reiterated that target, pointing to the rollout of its SMART Search and SMART Summary AI tools across Orion Health's global customer base as the structural lever that could meaningfully improve margins in 2027.

Yet the company has also walked back its growth guidance, now indicating that the lower end of its previously stated 30 to 50 percent range for the AI and Data Science segment is the realistic outcome — implying segment revenue of approximately C$13 million for the full year. That revision suggests enterprise contract integration is proceeding more slowly than initially communicated.

The stock remains roughly 56 percent below its 52-week high of €1.05, reached on August 13, 2025, a gap that underscores lingering skepticism about the company's ability to deliver on its projections. Automated charting tools have recently assessed the short-term trend with caution.

What Comes Next

The bull case rests on the trajectory rather than the quarter: 60 percent first-half revenue growth, a sharply improved cash flow profile, and a SpaceX stake that could provide a liquidity injection without requiring operational progress. The bear case is equally straightforward — EBITDA declined sequentially on flat revenue, guidance was trimmed, and the gap between current margins and the 10 percent target remains substantial with only a few months left to close it.

The annual results for 2026 will serve as the definitive checkpoint, determining whether the promised margin inflection translates into audited reality — and whether the SpaceX monetization, still contingent on lock-up expiry and prevailing market conditions, becomes a tangible balance-sheet event rather than a stated intention.